New antibody takes aim at Hard-to-Treat liver cancer
NCT ID NCT06795022
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This study tests a new drug called AZD9793 in people with advanced liver cancer that has spread. The drug is an antibody designed to help the body's immune cells find and attack cancer cells. The main goals are to check if the drug is safe and if it can shrink tumors. About 304 adults will take part in this early-phase trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD9793 (an antibody that helps immune cells attack cancer cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced liver cancer that has not responded to other therapies.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects from immune activation can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
WITHDRAWNLa Jolla, California, 92093, United States
-
Research Site
RECRUITINGLos Angeles, California, 90089, United States
-
Research Site
NOT_YET_RECRUITINGBaltimore, Maryland, 21201, United States
-
Research Site
NOT_YET_RECRUITINGBoston, Massachusetts, 02114, United States
-
Research Site
RECRUITINGSt Louis, Missouri, 63108, United States
-
Research Site
NOT_YET_RECRUITINGHackensack, New Jersey, 07601, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
RECRUITINGChengdu, 610041, China
-
Research Site
RECRUITINGGuangzhou, 510515, China
-
Research Site
NOT_YET_RECRUITINGHarbin, 150049, China
-
Research Site
RECRUITINGShanghai, 201114, China
-
Research Site
RECRUITINGPokfulam, 999077, Hong Kong
-
Research Site
RECRUITINGShatin, 000000, Hong Kong
-
Research Site
RECRUITINGKashiwa, 277-8577, Japan
-
Research Site
RECRUITINGYokohama, 241-8515, Japan
-
Research Site
NOT_YET_RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGSeoul, 5505, South Korea
-
Research Site
NOT_YET_RECRUITINGBarcelona, 8035, Spain
-
Research Site
NOT_YET_RECRUITINGPamplona, 31005, Spain
-
Research Site
RECRUITINGTaipei, 10002, Taiwan
-
Research Site
RECRUITINGTaoyuan, 333, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?